(Reuters) - NeuroDerm Ltd's shares more than doubled in value on Tuesday, after the company said data from a mid-stage study suggested that a higher dose of its Parkinson's drug could provide an alternative to treatments that require surgery. The trial evaluated two liquid formulations of the drug, levodopa/carbidopa (LD/CD), in 16 patients with an advanced form of the disease to assess its capacity to reduce Parkinson's-related motor complications, the Israel-based company said.Delivered through a belt-worn pump, the two versions of the drug,...